You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

269 Results
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Curative
Funding:
New Drug Funding Program
    Durvalumab - Locally Advanced Unresectable Stage III Non-Small Cell Lung Cancer Following Concurrent Chemoradiation
Jun 2024
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Neoadjuvant, Adjuvant
May 2019
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Neoadjuvant, Adjuvant
Aug 2018
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Neoadjuvant
Jan 2024
Regimen
Cancer Type:
Breast, 
Central Nervous System, 
Gastrointestinal, 
Colorectal, 
Esophagus, 
Gastric / Stomach, 
Hepatobiliary / Liver / Bile Duct, 
Pancreas, 
Genitourinary, 
Bladder / Urothelial, 
Prostate, 
Gynecologic, 
Cervix, 
Endometrial, 
Ovary, 
Head and Neck, 
Lung, 
Small Cell
Intent: Adjuvant, Curative, Palliative
Dec 2023
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Curative, Adjuvant
May 2019
Regimen
Intent: Adjuvant, Curative, Palliative
Funding:
ODB - General Benefit
  • triptorelin
May 2019
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative
Funding:
ODB - General Benefit
    dexamethasone
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec.
Apr 2024
Regimen
Cancer Type:
Head and Neck, 
Nasopharynx
Intent: Curative
Sep 2019
Regimen
Cancer Type:
Sarcoma, 
Osteogenic / Bone
Intent: Adjuvant, Neoadjuvant, Palliative
Sep 2019
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Intent: Adjuvant, Curative
Nov 2019
Regimen
Intent: Curative, Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Apr 2023

Pages